Effect of dexmedetomidine on Nociception Level Index-guided remifentanil antinociception: A randomised controlled trial.
Sean Coeckelenbergh, Stefano Doria, Daniel Patricio...
https://pubmed.ncbi.nlm.nih.gov/33259449/Actively Recruiting
Led by Ciusss de L'Est de l'Île de Montréal · Updated on 2026-10-23
72
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the effects of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, on reducing the need for opioids during laparoscopic abdominal surgery. Opioids, while effective for pain relief during surgery, have significant short- and long-term side effects. This trial aims to see if dexmedetomidine can lower intraoperative remifentanil consumption and improve post-surgery pain and recovery, including in patients with varying health statuses classified as ASA 1 to 3. Participants will be randomly assigned to receive either dexmedetomidine or a placebo normal saline during surgery. The dexmedetomidine is given as a 0.5 mcgkg bolus over 10 minutes during anesthesia induction, followed by a continuous infusion up to a maximum dose or until pneumoperitoneum is deflated. The placebo group receives an equivalent volume of saline. Treatments are delivered via an infusion pump during the surgery. During the study, researchers will monitor remifentanil consumption, blood pressure, heart rate, and other vital signs throughout surgery. Postoperative assessments include pain scores, opioid use in the recovery room, adverse events, time to extubation, and quality of recovery at 24 hours. The trial is designed to last from anesthesia induction to discharge from the post-anesthesia care unit, with follow-up on recovery and pain one day after surgery.
CONDITIONS
The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption
O
Olivier Verdonck
N
Nadia Godin
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ciusss de L'Est de l'Île de Montréal
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - From induction of anesthesia to end of surgery
Participants receive either a dexmedetomidine infusion or placebo saline during laparoscopic abdominal surgery under general anesthesia.
1 surgery visit
Duration - Up to 24 hours after surgery
Participants are monitored in the post-anesthesia care unit for pain, opioid use, vital signs, and recovery quality up to 24 hours after surgery.
1 recovery visit and 1 follow-up assessment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sean Coeckelenbergh, Stefano Doria, Daniel Patricio...
https://pubmed.ncbi.nlm.nih.gov/33259449/Ciusss de L'Est de l'Île de Montréal
Lead Sponsor